The U.S. Food and Drug Administration (FDA) is experiencing significant upheaval in its leadership, particularly within its cell and gene therapy divisions. Recent reports indicate that disagreements over therapy management styles may have contributed to the ousting of important officials, including Nicole Verdun, the former director of the Center for Biologics Evaluation and Research (CBER). This shakeup has led to a decline in gene therapy stocks, raising concerns and uncertainty within the industry. Notably, Capricor Therapeutics saw a 16% drop in its stock price following news of the departures. Experts warn that these changes could signify a major setback for ongoing research and development in gene therapies, further complicating the landscape for companies operating in this sector.